Squadron Capital Management Llc Portfolio Stock Holdings
According to the SEC 13F filed on August 14, 2026, Squadron Capital Management Llc disclosed 33 stock positions valued at approximately $292.09M as of quarter-end June 30, 2026. The largest holdings include RELMADA THERAPEUTICS INC, C4 THERAPEUTICS INC, and COGENT BIOSCIENCES INC.
- Report Period
- June 30, 2026
- No. of Stocks
- 33
- Portfolio Value
- $292.09M
Holdings by Sector
Squadron Capital Management Llc Portfolio Holdings in Q2 2026
| Company | Symbol | Sector | Portfolio % | Shares | Change (Shares) | Change % | Value |
|---|---|---|---|---|---|---|---|
| RELMADA THERAPEUTICS INC | RLMD | Healthcare | 17.41% | 7,350,000 | -1,124,571 | -13.27% | $50,862,000 |
| C4 THERAPEUTICS INC | CCCC | Healthcare | 11.51% | 7,200,000 | +4,950,000 | +220.00% | $33,624,000 |
| COGENT BIOSCIENCES INC | COGT | Healthcare | 11.46% | 865,000 | +77,508 | +9.84% | $33,475,500 |
| KODIAK SCIENCES INC | KOD | Healthcare | 6.67% | 500,000 | +120,000 | +31.58% | $19,480,000 |
| RELAY THERAPEUTICS INC | RLAY | Healthcare | 6.21% | 970,000 | +297,500 | +44.24% | $18,148,700 |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | Healthcare | 6.14% | 3,700,000 | +69,000 | +1.90% | $17,945,000 |
| EDGEWISE THERAPEUTICS INC | EWTX | Healthcare | 4.03% | 290,000 | -60,000 | -17.14% | $11,782,700 |
| MAZE THERAPEUTICS INC | MAZE | Other | 3.42% | 335,000 | +77,500 | +30.10% | $9,996,400 |
| INVENTIVA SA | IVA | Other | 3.15% | 2,435,000 | +1,900,000 | +355.14% | $9,204,300 |
| ADLAI NORTYE LTD | ANL | Other | 3.01% | 764,876 | -500,355 | -39.55% | $8,796,074 |
| ENLIVEN THERAPEUTICS INC | ELVN | Healthcare | 2.78% | 160,000 | +160,000 | +100.00% | $8,120,000 |
| PALISADE BIO INC | PALI | Other | 2.15% | 3,000,000 | - | - | $6,270,000 |
| INHIBIKASE THERAPEUTICS INC | IKT | Healthcare | 2.08% | 3,000,000 | -500,000 | -14.29% | $6,090,000 |
| ADAGENE INC | ADAG | Healthcare | 1.80% | 1,250,000 | +1,250,000 | +100.00% | $5,250,000 |
| INFLARX NV | IFRX | Other | 1.53% | 2,000,000 | +2,000,000 | +100.00% | $4,480,000 |
| ASSEMBLY BIOSCIENCES INC | ASMB | Healthcare | 1.51% | 160,000 | +160,000 | +100.00% | $4,396,800 |
| PROMIS NEUROSCIENCES INC | PMN | Other | 1.46% | 324,977 | - | - | $4,276,697 |
| CONTINEUM THERAPEUTICS INC | CTNM | Healthcare | 1.46% | 260,000 | +260,000 | +100.00% | $4,261,400 |
| COMPASS PATHWAYS PLC | CMPS | Healthcare | 1.45% | 300,000 | -88,287 | -22.74% | $4,245,000 |
| DEFINIUM THERAPEUTICS INC | DFTX | Other | 1.37% | 85,000 | +85,000 | +100.00% | $3,998,400 |
| SOL-GEL TECHNOLOGIES LTD | SLGL | Other | 1.32% | 52,000 | +21,000 | +67.74% | $3,855,280 |
| BIOAGE LABS INC | BIOA | Other | 1.30% | 155,000 | +155,000 | +100.00% | $3,799,050 |
| SCYNEXIS INC | SCYX | Other | 1.05% | 756,884 | -6,851,811 | -90.05% | $3,080,518 |
| PROQR THRAPEUTICS N V | PRQR | Other | 0.96% | 1,511,496 | +1,511,496 | +100.00% | $2,811,383 |
| REZOLUTE INC | RZLT | Healthcare | 0.72% | 403,410 | +403,410 | +100.00% | $2,097,732 |
| LIPOCINE INC NEW | LPCN | Healthcare | 0.71% | 810,000 | +360,000 | +80.00% | $2,073,600 |
| CUE BIOPHARMA INC | CUE | Other | 0.54% | 50,000 | +50,000 | +100.00% | $1,578,000 |
| CALCIMEDICA INC | CALC | Healthcare | 0.44% | 1,244,864 | +1,244,864 | +100.00% | $1,282,210 |
| QUINCE THERAPEUTICS INC | QNCX | Other | 0.25% | 40,375 | +40,375 | +100.00% | $734,421 |
| PASITHEA THERAPEUTICS CORP | KTTA | Other | 0.18% | 1,000,000 | -1,100,000 | -52.38% | $515,400 |
Showing 30 of 33 holdings in the latest reporting period.
Squadron Capital Management Llc Options Holdings in Q2 2026
| Quarter | Symbol | Company | Option | Contracts | Notional Value |
|---|---|---|---|---|---|
| Q2 2026 | AVBP | ArriVent BioPharma, Inc. | CALL | 183,000 | $6,357,420 |
| Q2 2026 | BIOA | BIOAGE LABS INC | CALL | 250,000 | $6,127,500 |
| Q2 2026 | RZLT | Rezolute, Inc. | CALL | 900,000 | $4,680,000 |
| Q2 2026 | CMPS | COMPASS Pathways Plc - American | CALL | 305,000 | $4,315,750 |
| Q2 2026 | IRON | Disc Medicine, Inc. | CALL | 30,000 | $2,194,200 |
| Q2 2026 | ZNTL | Zentalis Pharmaceuticals, Inc. | CALL | 426,000 | $2,066,100 |
| Q2 2026 | CCCC | C4 Therapeutics, Inc. | CALL | 400,000 | $1,868,000 |
| Q2 2026 | RARE | Ultragenyx Pharmaceutical Inc. | CALL | 55,000 | $1,836,450 |
| Q2 2026 | NVCT | Nuvectis Pharma, Inc. | CALL | 38,700 | $711,693 |
Showing 9 of 9 options positions in the latest reporting period.
Notional value represents the total exposure of the options position.